Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.46 |
| ▸ | POLB | P06746 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3062839 | 1.00 | CCR1 (0.54) | CCR1MEN1KMT2ALMNATP53 | |
| SCHEMBL3080138 | 0.86 | MEN1 (0.48) | CCR1MEN1KMT2ALMNATP53 | |
| SCHEMBL3080134 | 0.86 | MEN1 (0.48) | CCR1MEN1KMT2ALMNATP53 | |
| SCHEMBL3076768 | 0.86 | MEN1 (0.63) | CCR1MEN1KMT2ALMNATP53 | |
| SCHEMBL3066554 | 0.79 | CCR1 (0.55) | CCR1MEN1KMT2ALMNAPOLB | |
| SCHEMBL3076604 | 0.79 | MEN1 (0.57) | CCR1MEN1KMT2AMAOAMAOB | |
| SCHEMBL13140328 | 0.79 | MEN1 (0.55) | CCR1MEN1KMT2ALMNATP53 | |
| SCHEMBL3076494 | 0.78 | CCR1 (0.54) | CCR1MEN1KMT2ALMNATP53 | |
| SCHEMBL13140386 | 0.78 | CCR1 (0.56) | CCR1MEN1KMT2ALMNAPOLB | |
| SCHEMBL2875351 | 0.78 | CCR1 (0.62) | CCR1SUV39H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790726-B2 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CCR1, CCR3, CCR4 | CCR1 1/4885MEN1 3626/4885KMT2A 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.